OraSure (OSUR) Technologies announced its OraQuick HIV Self-Test has received a license from Health Canada for use in Canada. The OraQuick HIV Self-Test is a point-of-care rapid antibody test. It is Canada’s first oral HIV self-test and detects antibodies for both HIV-1 and HIV-2.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSUR:
- OraSure confirms receipt of director nominations from Altai Capital
- Altai Capital Management nominates two candidates to OraSure board
- OraSure Seeks FDA Clearance for New STI Tests
- OraSure submits CT/NG molecular self-test, Colli-Pee device for FDA review
- OraSure confirms Altai Capital intent to nominate two board members